934 related articles for article (PubMed ID: 34479543)
1. Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents.
Tanaka A; Toyoda S; Imai T; Shiina K; Tomiyama H; Matsuzawa Y; Okumura T; Kanzaki Y; Onishi K; Kiyosue A; Nishino M; Sakata Y; Node K;
Cardiovasc Diabetol; 2021 Sep; 20(1):175. PubMed ID: 34479543
[TBL] [Abstract][Full Text] [Related]
2. Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial.
Kusunose K; Imai T; Tanaka A; Dohi K; Shiina K; Yamada T; Kida K; Eguchi K; Teragawa H; Takeishi Y; Ohte N; Yamada H; Sata M; Node K;
Cardiovasc Diabetol; 2021 Sep; 20(1):186. PubMed ID: 34521417
[TBL] [Abstract][Full Text] [Related]
3. Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction.
Januzzi JL; Xu J; Li J; Shaw W; Oh R; Pfeifer M; Butler J; Sattar N; Mahaffey KW; Neal B; Hansen MK
J Am Coll Cardiol; 2020 Nov; 76(18):2076-2085. PubMed ID: 33121714
[TBL] [Abstract][Full Text] [Related]
4. Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.
Tanaka A; Inoue T; Kitakaze M; Oyama J; Sata M; Taguchi I; Shimizu W; Watada H; Tomiyama H; Ako J; Sakata Y; Anzai T; Uematsu M; Suzuki M; Eguchi K; Yamashina A; Saito Y; Sato Y; Ueda S; Murohara T; Node K
Cardiovasc Diabetol; 2016 Apr; 15():57. PubMed ID: 27044332
[TBL] [Abstract][Full Text] [Related]
5. Canagliflozin for Japanese patients with chronic heart failure and type II diabetes.
Sezai A; Sekino H; Unosawa S; Taoka M; Osaka S; Tanaka M
Cardiovasc Diabetol; 2019 Jun; 18(1):76. PubMed ID: 31167663
[TBL] [Abstract][Full Text] [Related]
6. Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE).
Tanaka A; Hisauchi I; Taguchi I; Sezai A; Toyoda S; Tomiyama H; Sata M; Ueda S; Oyama JI; Kitakaze M; Murohara T; Node K;
ESC Heart Fail; 2020 Aug; 7(4):1585-1594. PubMed ID: 32349193
[TBL] [Abstract][Full Text] [Related]
7. Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure: A subanalysis of the randomized CANDLE trial.
Tanaka A; Imai T; Shimabukuro M; Nakamura I; Matsunaga K; Ozaki Y; Minamino T; Sata M; Node K;
J Diabetes Investig; 2022 Dec; 13(12):1990-1999. PubMed ID: 36114704
[TBL] [Abstract][Full Text] [Related]
8. Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis.
Yu YW; Zhao XM; Wang YH; Zhou Q; Huang Y; Zhai M; Zhang J
Cardiovasc Diabetol; 2021 Jan; 20(1):25. PubMed ID: 33494751
[TBL] [Abstract][Full Text] [Related]
9. Association between serum insulin levels and heart failure-related parameters in patients with type 2 diabetes and heart failure treated with canagliflozin: a post-hoc analysis of the randomized CANDLE trial.
Tanaka A; Imai T; Shimabukuro M; Taguchi I; Sezai A; Toyoda S; Watada H; Ako J; Node K;
Cardiovasc Diabetol; 2022 Aug; 21(1):151. PubMed ID: 35941584
[TBL] [Abstract][Full Text] [Related]
10. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program.
Rådholm K; Figtree G; Perkovic V; Solomon SD; Mahaffey KW; de Zeeuw D; Fulcher G; Barrett TD; Shaw W; Desai M; Matthews DR; Neal B
Circulation; 2018 Jul; 138(5):458-468. PubMed ID: 29526832
[TBL] [Abstract][Full Text] [Related]
11. How should we monitor the cardiovascular benefit of sodium-glucose cotransporter 2 inhibition?
Tanaka A; Node K
Cardiovasc Diabetol; 2020 Dec; 19(1):206. PubMed ID: 33287812
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin.
Tanaka A; Shimabukuro M; Teragawa H; Okada Y; Takamura T; Taguchi I; Toyoda S; Tomiyama H; Ueda S; Higashi Y; Node K;
Cardiovasc Diabetol; 2021 Jul; 20(1):160. PubMed ID: 34332584
[TBL] [Abstract][Full Text] [Related]
13. Body fluid regulation via chronic inhibition of sodium-glucose cotransporter-2 in patients with heart failure: a post hoc analysis of the CANDLE trial.
Fujiki S; Tanaka A; Imai T; Shimabukuro M; Uehara H; Nakamura I; Matsunaga K; Suzuki M; Kashimura T; Minamino T; Inomata T; Node K;
Clin Res Cardiol; 2023 Jan; 112(1):87-97. PubMed ID: 35729430
[TBL] [Abstract][Full Text] [Related]
14. Influence of left ventricular ejection fraction on the reduction in N-terminal pro-brain natriuretic peptide by canagliflozin in patients with heart failure and type 2 diabetes: A sub analysis of the CANDLE trial.
Ohte N; Tanaka A; Kitada S; Yamada T; Eguchi K; Teragawa H; Takeishi Y; Kodama K; Seo Y; Node K;
J Cardiol; 2023 Jun; 81(6):508-512. PubMed ID: 36481298
[TBL] [Abstract][Full Text] [Related]
15. Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes.
Januzzi JL; Butler J; Jarolim P; Sattar N; Vijapurkar U; Desai M; Davies MJ
J Am Coll Cardiol; 2017 Aug; 70(6):704-712. PubMed ID: 28619659
[TBL] [Abstract][Full Text] [Related]
16. Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial.
Shiina K; Tomiyama H; Tanaka A; Imai T; Hisauchi I; Taguchi I; Sezai A; Toyoda S; Dohi K; Kamiya H; Kida K; Anzai T; Chikamori T; Node K;
Hypertens Res; 2023 Feb; 46(2):495-506. PubMed ID: 36380202
[TBL] [Abstract][Full Text] [Related]
17. Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study.
Tamaki S; Yamada T; Watanabe T; Morita T; Furukawa Y; Kawasaki M; Kikuchi A; Kawai T; Seo M; Abe M; Nakamura J; Yamamoto K; Kayama K; Kawahira M; Tanabe K; Fujikawa K; Hata M; Fujita Y; Umayahara Y; Taniuchi S; Sanada S; Shintani A; Fukunami M
Circ Heart Fail; 2021 Mar; 14(3):e007048. PubMed ID: 33663235
[TBL] [Abstract][Full Text] [Related]
18. Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF).
Jensen J; Omar M; Kistorp C; Poulsen MK; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Fosbøl E; Bruun NE; Videbæk L; Frederiksen PH; Møller JE; Schou M
Trials; 2019 Jun; 20(1):374. PubMed ID: 31227014
[TBL] [Abstract][Full Text] [Related]
19. Effect of canagliflozin on nocturnal home blood pressure in Japanese patients with type 2 diabetes mellitus: The SHIFT-J study.
Kario K; Hoshide S; Okawara Y; Tomitani N; Yamauchi K; Ohbayashi H; Itabashi N; Matsumoto Y; Kanegae H
J Clin Hypertens (Greenwich); 2018 Oct; 20(10):1527-1535. PubMed ID: 30246286
[TBL] [Abstract][Full Text] [Related]
20. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
Nassif ME; Windsor SL; Tang F; Khariton Y; Husain M; Inzucchi SE; McGuire DK; Pitt B; Scirica BM; Austin B; Drazner MH; Fong MW; Givertz MM; Gordon RA; Jermyn R; Katz SD; Lamba S; Lanfear DE; LaRue SJ; Lindenfeld J; Malone M; Margulies K; Mentz RJ; Mutharasan RK; Pursley M; Umpierrez G; Kosiborod M
Circulation; 2019 Oct; 140(18):1463-1476. PubMed ID: 31524498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
